As of Jan 10, 2025, BioNTech SE's Discounted Cash Flow (DCF) valuation estimates its share price at $225.1. This suggests it may be undervalued by 83.2% compared to its current price of around $122.9, using a WACC of 8.0% and growth rates of 3.0%.
As of Jan 10, 2025, BioNTech SE's Weighted Average Cost of Capital (WACC) is approximately 8.0%.
As of Jan 10, 2025, BioNTech SE's Enterprise Value (EV) is approximately €36.6B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.